scFv(GPC3)-CD28-CD3zeta CAR-T Lentivirus

The scFv(GPC3)-CD28-CD3zeta CAR-T lentivirus is a gene delivery system designed for the efficient transduction of human primary T lymphocytes. As a member of the retroviridae family, lentiviral vectors have become the gold standard for adoptive cell therapy due to their inherent structural and functional advantages. Unlike standard retroviruses, lentiviruses possess the unique ability to infect both dividing and non-dividing cells, which is crucial for the genetic modification of resting T cells isolated from clinical samples. The vector structure employed in this specific anti-GPC3 CAR incorporates a self-inactivation (SIN) design, significantly reducing the risk of insertional mutations and ensuring the safety of modified cells. Furthermore, the lentiviral system exhibits robust packaging capabilities, seamlessly integrating complex genetic circuits—including a single-stranded variable fragment (scFv) targeting GPC3, a CD28 co-stimulatory domain, and a CD3-zeta signal tail—into the host cell genome. This stable integration ensures constitutive expression of the chimeric antigen receptor (CAR) on the T cell surface and its delivery to daughter cells during amplification, thereby conferring durable antitumor potential.

The primary application of scFv(GPC3)-CD28-CD3ζ CAR-T lentiviruses lies in the development of targeted immunotherapies for solid tumors, particularly those overexpressing glycoprotein-3 (GPC3). GPC3 is a cell surface oncoemulsifiable protein highly expressed in hepatocellular carcinoma (HCC), yolk sac tumors, and certain squamous cell carcinomas of the lung, but not expressed or expressed at very low levels in healthy adult tissues. This makes it an ideal target for chimeric antigen receptor (CAR) T-cell therapy. Researchers have used these lentiviral particles to generate CAR-T cells for rigorous in vitro functional assays, including cell-mediated cytotoxicity assays. In these assays, CAR-T cells are co-cultured with targeted cancer cell lines to measure their killing efficiency. Furthermore, these modified cells are crucial for in vivo studies using patient-derived xenograft (PDX) or cell-derived xenograft (CDX) mouse models, which can evaluate the infiltration, durability, and antitumor efficacy of CAR-T therapy under complex physiological conditions.